BIOMAT Database Logo BIOMAT Database Logo

Cyclophosphamide therapy for rheumatoid arthritis. 1975

C J Smyth, and B A Bartholomew, and D M Mills, and J C Steigerwald, and S J Strong, and S Recart

Cyclophosphamide in high doses was given for six months to 19 patients with rheumatoid arthritis. A second group of patients with rheumatoid arthritis whose conditions were stable on low-dose prednisone received in addition either cyclophosphamide or placebo for six months. Measurements of joint function and joint inflammation were used to estimate disease activity. Joint inflammation progressively decreased and joint function improved in the high-dose group. The low-dose cyclophosphamide-plus-prednisone group had a similar response that was different from the prednisone-plus-placebo group. Cyclophosphamide toxicity was common in the high-dose group and minimal in the low-dose-plus-prednisone group. Cyclophosphamide therapy improved the arthritis of these patients. The results were almost as good in the low-dose-plus-prednisone group, and the toxicity was much less.

UI MeSH Term Description Entries
D007958 Leukocyte Count The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells. Blood Cell Count, White,Differential Leukocyte Count,Leukocyte Count, Differential,Leukocyte Number,White Blood Cell Count,Count, Differential Leukocyte,Count, Leukocyte,Counts, Differential Leukocyte,Counts, Leukocyte,Differential Leukocyte Counts,Leukocyte Counts,Leukocyte Counts, Differential,Leukocyte Numbers,Number, Leukocyte,Numbers, Leukocyte
D008124 Locomotion Movement or the ability to move from one place or another. It can refer to humans, vertebrate or invertebrate animals, and microorganisms. Locomotor Activity,Activities, Locomotor,Activity, Locomotor,Locomotor Activities
D008297 Male Males
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D011241 Prednisone A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver. Dehydrocortisone,delta-Cortisone,Apo-Prednisone,Cortan,Cortancyl,Cutason,Dacortin,Decortin,Decortisyl,Deltasone,Encorton,Encortone,Enkortolon,Kortancyl,Liquid Pred,Meticorten,Orasone,Panafcort,Panasol,Predni Tablinen,Prednidib,Predniment,Prednison Acsis,Prednison Galen,Prednison Hexal,Pronisone,Rectodelt,Sone,Sterapred,Ultracorten,Winpred,Acsis, Prednison
D001799 Blood Sedimentation Measurement of rate of settling of ERYTHROCYTES in blood. Erythrocyte Sedimentation,Erythrocyte Sedimentation Rate,Erythrocyte Sedimentation Rates,Rate, Erythrocyte Sedimentation,Rates, Erythrocyte Sedimentation,Sedimentation Rate, Erythrocyte,Sedimentation Rates, Erythrocyte,Sedimentation, Blood,Sedimentation, Erythrocyte
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004064 Digestive System A group of organs stretching from the MOUTH to the ANUS, serving to breakdown foods, assimilate nutrients, and eliminate waste. In humans, the digestive system includes the GASTROINTESTINAL TRACT and the accessory glands (LIVER; BILIARY TRACT; PANCREAS). Ailmentary System,Alimentary System
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug

Related Publications

C J Smyth, and B A Bartholomew, and D M Mills, and J C Steigerwald, and S J Strong, and S Recart
Cyclophosphamide therapy of rheumatoid arthritis.
January 1973, Ryumachi. [Rheumatism],
C J Smyth, and B A Bartholomew, and D M Mills, and J C Steigerwald, and S J Strong, and S Recart
Cyclophosphamide therapy for severe juvenile rheumatoid arthritis.
June 1971, American journal of diseases of children (1960),
C J Smyth, and B A Bartholomew, and D M Mills, and J C Steigerwald, and S J Strong, and S Recart
Cyclophosphamide for rheumatoid arthritis.
January 2000, The Cochrane database of systematic reviews,
C J Smyth, and B A Bartholomew, and D M Mills, and J C Steigerwald, and S J Strong, and S Recart
Cyclophosphamide pulse in combination therapy for refractory rheumatoid arthritis.
January 1996, The Journal of rheumatology,
C J Smyth, and B A Bartholomew, and D M Mills, and J C Steigerwald, and S J Strong, and S Recart
Long-term cyclophosphamide therapy in rheumatoid arthritis.
April 1968, Arthritis and rheumatism,
C J Smyth, and B A Bartholomew, and D M Mills, and J C Steigerwald, and S J Strong, and S Recart
Cyclophosphamide for treating rheumatoid arthritis.
January 2000, The Cochrane database of systematic reviews,
C J Smyth, and B A Bartholomew, and D M Mills, and J C Steigerwald, and S J Strong, and S Recart
Cooperating clinics committee. Cyclophosphamide therapy of rheumatoid arthritis.
January 1971, Arthritis and rheumatism,
C J Smyth, and B A Bartholomew, and D M Mills, and J C Steigerwald, and S J Strong, and S Recart
Prospective pilot study of intravenous pulse cyclophosphamide therapy for refractory rheumatoid arthritis.
July 1989, Arthritis and rheumatism,
C J Smyth, and B A Bartholomew, and D M Mills, and J C Steigerwald, and S J Strong, and S Recart
Cyclophosphamide treatment of rheumatoid arthritis.
October 1969, Arthritis and rheumatism,
C J Smyth, and B A Bartholomew, and D M Mills, and J C Steigerwald, and S J Strong, and S Recart
[Cyclophosphamide in the therapy of rheumatoid arthritis and its complications].
June 2007, Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego,
Copied contents to your clipboard!